SG11202011313UA - Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins - Google Patents

Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins

Info

Publication number
SG11202011313UA
SG11202011313UA SG11202011313UA SG11202011313UA SG11202011313UA SG 11202011313U A SG11202011313U A SG 11202011313UA SG 11202011313U A SG11202011313U A SG 11202011313UA SG 11202011313U A SG11202011313U A SG 11202011313UA SG 11202011313U A SG11202011313U A SG 11202011313UA
Authority
SG
Singapore
Prior art keywords
knock
cells
generation
out primary
expanded human
Prior art date
Application number
SG11202011313UA
Inventor
Dean Anthony Lee
Kararoudi Meisam Naeimi
Original Assignee
Res Inst Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens Hospital filed Critical Res Inst Nationwide Childrens Hospital
Publication of SG11202011313UA publication Critical patent/SG11202011313UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
SG11202011313UA 2018-05-16 2019-05-16 Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins SG11202011313UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862672368P 2018-05-16 2018-05-16
PCT/US2019/032670 WO2019222503A1 (en) 2018-05-16 2019-05-16 Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins

Publications (1)

Publication Number Publication Date
SG11202011313UA true SG11202011313UA (en) 2020-12-30

Family

ID=68541163

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011313UA SG11202011313UA (en) 2018-05-16 2019-05-16 Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins

Country Status (12)

Country Link
US (1) US20210228630A1 (en)
EP (1) EP3796924A4 (en)
JP (1) JP2021523725A (en)
KR (1) KR20210013077A (en)
CN (1) CN113518826A (en)
AU (1) AU2019271366A1 (en)
BR (1) BR112020023232A2 (en)
CA (1) CA3100341A1 (en)
IL (1) IL278723B1 (en)
MX (1) MX2020012208A (en)
SG (1) SG11202011313UA (en)
WO (1) WO2019222503A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022008215A2 (en) * 2019-10-31 2022-07-12 Res Inst Nationwide Childrens Hospital GENERATION OF PRIMARY AND EXPANDED HUMAN NK CELLS CD38 KNOCK-OUT
US20230181637A1 (en) * 2020-03-11 2023-06-15 Research Institute At Nationwide Children's Hospital Nk cells and uses thereof for treatment of microbial infections
CN111607569A (en) * 2020-06-01 2020-09-01 广东昭泰体内生物医药科技有限公司 Method for reprogramming ITNK cells based on CRISPR/Cas9
AU2021294317A1 (en) * 2020-06-26 2023-02-23 Csl Behring Llc Donor T-cells with kill switch
CA3225985A1 (en) 2021-07-01 2023-01-05 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
WO2023081200A2 (en) * 2021-11-03 2023-05-11 Intellia Therapeutics, Inc. Cd38 compositions and methods for immunotherapy
WO2024007020A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018200A1 (en) * 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Improved method for the generation of genetically modified cells
CA2986314A1 (en) * 2015-06-30 2017-01-05 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
CN108026512B (en) * 2015-07-29 2022-09-16 昂克医疗有限公司 Modified natural killer cells and natural killer cell lines with enhanced cytotoxicity
EP3328399B1 (en) * 2015-07-31 2023-12-27 Regents of the University of Minnesota Modified cells and methods of therapy
WO2017214569A1 (en) * 2016-06-09 2017-12-14 Regents Of The University Of Minnesota Genome-edited nk cell and methods of making and using
CN109844099B (en) * 2016-07-25 2024-01-02 美国政府(由卫生和人类服务部的部长所代表) Methods of producing modified natural killer cells and methods of use
ES2926397T3 (en) * 2016-12-09 2022-10-26 Onk Therapeutics Ltd Engineered natural killer cells and their uses
CN110913870A (en) * 2016-12-30 2020-03-24 细胞结构公司 Genetically modified natural killer cells
EP3634437A4 (en) * 2017-05-19 2020-11-18 Case Western Reserve University Compositions and methods for expanding ex vivo natural killer cells and therapeutic uses thereof
EP3788061A4 (en) * 2018-05-03 2022-02-23 Board of Regents, The University of Texas System Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade

Also Published As

Publication number Publication date
BR112020023232A2 (en) 2021-02-23
MX2020012208A (en) 2021-03-02
IL278723A (en) 2021-03-01
WO2019222503A1 (en) 2019-11-21
JP2021523725A (en) 2021-09-09
CA3100341A1 (en) 2019-11-21
KR20210013077A (en) 2021-02-03
EP3796924A1 (en) 2021-03-31
AU2019271366A1 (en) 2021-01-14
EP3796924A4 (en) 2022-01-12
US20210228630A1 (en) 2021-07-29
CN113518826A (en) 2021-10-19
IL278723B1 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
IL278723A (en) Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
EP4051297A4 (en) Generation of cd38 knock-out primary and expanded human nk cells
EP3638157A4 (en) Expandable intervertebral implant and related methods
IL271261A (en) Expandable sheath and methods of using the same
EP3368660A4 (en) Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
IL284196A (en) Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
GB2571871B (en) Asynchronous local and remote generation of consistent point-in-time snap copies
EP3532605A4 (en) Improved generation of muscle lineage cells and therapeutic uses thereof
EP3675991A4 (en) Free radical generator and methods of use
SG11202104334SA (en) Two-gene vectors for generating car-t cells and uses thereof
IL280240A (en) Nef-containing t cells and methods of producing thereof
EP3573242A4 (en) Frequency generator and frequency generation method
SG11202008353RA (en) Memory cell and method of forming the same
EP3420075A4 (en) Generation of cancer stem cells and use thereof
IL273757A (en) Expansion and use of expanded nk cell fractions
EP3532777A4 (en) Steam generator and reactor
IL276445A (en) Car-t cells and autoimmune diseases
IL281187A (en) Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
EP3712268A4 (en) Transformed human cell and use thereof
SG11202105217RA (en) Placenta-derived allogeneic car-t cells and uses thereof
EP3805163A4 (en) Electrolyzed water generator and electrolyzed water generation system
KR102292781B9 (en) - PolyglycolidePGA-polylactidePLA muliblock copolymer and method of synthesis of the same
EP3734955A4 (en) Image generation method and image synthesis method
GB2572330B (en) Devices and methods for generating electricity
EP3529397A4 (en) Ozone generators, methods of making ozone generators, and methods of generating ozone